Diaper Rash Products

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

(PDF Version - 99.2 KB)

Date

2018-12-07

FOREWORD

This monograph is intended to replace the existing Diaper Rash Products Monograph of May 3, 2007. This monograph describes the requirements necessary to receive market authorization [i.e. a Drug Identification Number (DIN) or a Natural Product Number (NPN)], for diaper rash products. The monograph identifies the permitted medicinal and non-medicinal ingredients, concentrations, indications, directions and conditions of use for these products to be market authorized without the submission to Health Canada of additional evidence. It also may contain the test methods recommended to be used to comply with the requirements of this monograph. Products which do not meet the criteria outlined in this document can apply for market authorization outside of the monograph stream.

Applicants are reminded that diaper rash products, like other non-prescription drugs or natural health products, are subject to the Food and Drug Regulations or the Natural Health Products Regulations administered by the Natural and Non-prescription Health Products Directorate (NNHPD). This includes requirements related to labelling, manufacturing and product specifications. Additional information on labels, outside of those specified in the monograph, such as additional directions for use and/or non-therapeutic claims are acceptable as long as they meet the Guidelines for the Nonprescription and Cosmetic Industry Regarding Non-therapeutic Advertising and Labelling Claims, the Guidelines for Consumer Advertising of Health products for Nonprescription drugs, Natural Health Products, Vaccines and Medical Devices, and are not false, misleading or counterintuitive to the use of the product.

The development of this monograph is the result of a thorough review of existing regulations, guidance documents, policies and current practices within Health Canada and other leading regulatory agencies.

Note

The solidus (/) indicates that the terms and/or the statements are synonymous. Either term or statement may be selected by the applicant. Text in parentheses is additional optional information which can be included on the Product Licence Application form and label at the applicant's discretion.

MEDICINAL INGREDIENT(S)

Diaper rash products are classified as natural health products (NHPs) if they contain ingredients from Tables 1 and 2. Applicants applying for an NPN can access the appropriate forms and guidance at: https://www.canada.ca/en/health-canada/services/drugs-health-products/natural-non-prescription.html.

Diaper rash products are classified as non-prescription drugs if they contain at least one ingredient from Table 3 at a quantity listed. Applicants applying for a DIN can access the appropriate forms and guidance at: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents.html.

Table 1: NHP medicinal ingredients
Proper name(s)¹	Common name(s)¹	Source material(s)¹				Quantity²
Proper name(s)¹	Common name(s)¹	Proper name(s)	Common name(s)	Part(s)	Preparation(s)	Quantity²
Table 1 Footnotes Table 1 Footnote 1 At least one of the following references was consulted per proper name, common name, and source material: O'Neil et al. 2018; Nikitakis and Lange 2016; Sweetman 2017; USP 41; NF 36. Return to Table 1 footnote1 referrer Table 1 Footnote 2 At least one of the following references was consulted for the dosage: Krinsky 2017; Sweetman 2017; Leung and Foster 2010; FDA 2003. Return to Table 1 footnote2 referrer Table 1 Footnote 3 Ingredient must be pharmacopoeial grade (for a list of acceptable pharmacopoeial grades, see the Quality of Natural Health Products Guide). Return to Table 1 footnote3 referrer
(2,5-Dioxo-4-imidazolidinyl)urea	Allantoin N-(2,5-Dioxo-4-imidazolidinyl) urea Glyoxyldiureide 5-Ureidohydantoin	N/A	Common name(s)	Allantoin³	Preparation(s)	N/A	N/A	0.5 - 2%
Iron oxide (Fe2O3), mixture with zinc oxide	Calamine	N/A	Calamine³	N/A	N/A	1 - 25%
Kaolin	Argilla Bolus alba China clay Hydrated aluminum silicate Kaolin Porcelain clay White bole	N/A	Kaolin³	N/A	N/A	4 - 20%
Talc	Talc Talcum	N/A	Talc³	N/A	N/A	45 - 100%
Zea mays	Corn Starch Starch - Maize Topical starch Zea Mays (Corn) Starch Zea mays starch	Zea mays³	N/A	Seed	Dried	10 - 98%
Zinc oxide	C.I. No. 77947 Zinc oxide	N/A	Zinc oxide³	N/A	N/A	1 - 25% (Zinc oxide) 1 - 40% (Zinc oxide ointment)

Table 2: Complementary NHP ingredients (safety only)³
Proper name(s)¹	Common name(s)¹	Source material(s)¹			Quantity²
Proper name(s)¹	Common name(s)¹	Proper name(s)	Common name(s)	Part(s)	Quantity²
Table 1 Footnotes Table 1 Footnote 1 At least one of the following references was consulted per proper name, common name, and source material: O'Neil et al. 2018; Sweetman 2017; Nikitakis and Lange 2016; USP 41; NF 36. Return to Table 1 footnote1 referrer Table 1 Footnote 2 The following reference was consulted for the dosage: FDA 2003. Return to Table 2 footnote2 referrer Table 1 Footnote 3 Cod liver oil and Lanolin are not permitted as single medicinal ingredients as these ingredients are not sufficient on their own to support the efficacy of the product. Return to Table 2 footnote3 referrer
Cod liver oil	Cod liver oil Lecoris aselli oleum	N/A	Gadidae	Liver	5 - 14%
Anhydrous lanolin Lanolin	Lanolin Wool fat	Ovis aries	N/A	Wool	15.5%

Table 3: Non-prescription drug medicinal ingredients¹
Proper name(s)	Common name(s)	Source material(s)	Quantity
Proper name(s)	Common name(s)	Common name(s)	Quantity
Table 3 Footnotes Table 3 Footnote 1 See Permitted combinations. Return to Table 1 footnote1 referrer
alpha-(Trimethylsilyl) -omega-methylpoly(oxy(dimethylsilylene)) Dimethicone Dimethyl polysiloxane	Dimethicone	Dimethicone	1 - 30%
Mineral oil	Liquid paraffin Mineral oil Paraffin oil Paraffinum liquidum Petrolatum, liquid White mineral oil	Mineral oil	50 - 100%
Petrolatum	Petrolatum Petroleum jelly	Petrolatum	30 - 100%
White petrolatum	White petrolatum White petroleum jelly	White petrolatum	30 - 100%

ROUTE(S) OF ADMINISTRATION

Topical

DOSAGE FORM(S)

Acceptable dosage forms for the age category listed in this monograph and specified route of administration are indicated in the Compendium of Monographs Guidance Document.

USE(S) OR PURPOSE(S)

Self-Care Framework Category I Uses or Purposes:

For all products:

Helps prevent diaper rash (FDA 2003).
Protects chafed skin due to diaper rash (FDA 2003).
Helps protect from wetness that causes diaper rash (FDA 2003).

For Allantoin, Calamine, Kaolin, Zinc oxide, Dimethicone, Mineral oil, Petrolatum, White petrolatum:

Temporarily protects and helps relieve minor skin irritation due to diaper rash (FDA 2003).

For products containing Calamine, Kaolin and/or Zinc oxide:

Helps treat/ heal diaper rash (FDA 2003).

DOSE(S)

Subpopulation(s)

Infants 0 to 1 years, Children 2 to 11 years, Adolescents 12 to 17 years, Adults 18 years and older

Quantity:

See Tables 1, 2, and 3 above.

Permitted combinations:

Any combination of the ingredients listed in Tables 1, 2 and/or 3 is permitted provided each ingredient in the combination is within the specified quantity (FDA 2003).

Directions for use:

For all products:

Apply liberally to a clean and dry diaper area as needed (FDA 2003).

Duration of use

No statement is required.

RISK INFORMATION

Caution(s) and warning(s)

For all products:

For external use only.(FDA 2003).
When using this product avoid contact with eyes. If contact occurs, rinse thoroughly with water (FDA 2003).
Stop use and ask/ consult a doctor/ physician/ health care practitioner/ health care provider/ health care professional if symptoms worsen or last for more than 7 days (FDA 2003).
Keep out of reach of children.If swallowed, call a poison control centre or get medical help right away.

For all powder products:

When using this product keep powder away from face to avoid inhalation, which can cause breathing problems (FDA 2003).

Contraindication(s)

For all powder products:

Do not use on broken skin (FDA 2003).

Known adverse reaction(s):

No statement required.

NON-MEDICINAL INGREDIENTS

Ingredients must be chosen from the current Natural Health Products Ingredients Database (NHPID) and must meet the limitations outlined in that database, the Food and Drug Regulations (FDR), and the current Cosmetic Ingredient Hotlist, when relevant.

STORAGE CONDITION(S)

No statement required.

SPECIFICATIONS

This monograph describes those requirements that are specific to this class of non-prescription drugs and to NHPs. Any change to the manufacturing process that impacts the safety and efficacy of the ingredients, such as the use of novel technology (e.g. nanotechnology), requires supporting data and will be reviewed outside the monograph.

For products containing Table 1 and 2 NHP medicinal ingredients only:

The finished product specifications must be established in accordance with the requirements described in the NNHPD Quality of Natural Health Products Guide. The medicinal ingredient must comply with the requirements outlined in the NHPID.

For products containing Table 3 non-prescription drug medicinal ingredients:

Requirements described in the Regulations to the Food and Drugs Act must be met.

DRUG FACTS TABLES (Format Optional for Self-Care Category I)

Drug Facts Table

References

FDA 2003: USA Department of Health and Human Services: Food and Drug Administration.21 CFR Part 347. Skin protectant products for Over-the-Counter Human Use, Final Monograph; 2003. [Accessed 2018-09-28]. Available at: https://www.gpo.gov/fdsys/pkg/FR-2003-06-04/pdf/03-13751.pdf

Krinsky DL, Ferreri SP, Hemstreet B, Hume AL, Newton GD, Rollins CJ, Tietze KJ. Handbook of Nonprescription Drugs: An interactive approach for Self-Care, 19^th edition. Washington (DC): American Pharmaceutical Association; 2017.

Leung AY, Foster S. Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics, 3rd edition. Hoboken (NJ): John Wiley and Sons, Inc.; 2010

Nikitakis J, Lange B, editors. International Cosmetic Ingredient Dictionary and Handbook. 16th edition. Washington (DC): Cosmetic, Toiletry and Fragrance Association; 2016.

NF 36: United States Pharmacopeia and the National Formulary (USP 41/NF 36). Rockville (MD): The United States Pharmacopeial Convention, Inc.; 2018.

O'Neil MJ, Smith A, Heckelman PE, Budavari S, editors. Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals, 2018. WhitehouseStation (NJ): Merck & Co., Inc; 2018.

Sweetman SC, editor. Martindale: The Complete Drug Reference, 39^th edition. Grayslake (IL): Pharmaceutical Press; 2017.

USP 41: United States Pharmacopeia and the National Formulary (USP 41/NF 36). Rockville (MD): The United States Pharmacopeial Convention, Inc.; 2007 (2018).